Adrenoceptors, calcium, and vasoconstriction in normal and hypertensive humans.
The sympathetic nervous activity contributes to the pathophysiology of essential hypertension in an early phase and in younger patients mainly through increased beta-adrenoceptor-mediated functions and in a later phase and in older patients in whom beta-adrenoceptor-mediated functions are blunted, through increased alpha-adrenoceptor-mediated and calcium-influx-dependent vasoconstriction. Intracellular free calcium concentration is elevated in platelets of hypertensive patients and relates directly to the degree of their blood pressure, likely reflecting increased intracellular calcium concentration in vascular smooth muscle cells. A sympathetic factor is suggested further by the enhanced alpha 1-and alpha 2-adrenoceptor-mediated and calcium influx-dependent, vasoconstriction both of which are normalized by antihypertensive treatment in parallel with a normalization of intracellular free calcium and of the increased adrenaline sensitivity of platelets. The higher sensitivity to adrenaline for thrombin-induced calcium increases in platelets of hypertensive patients indicates potentiation of calcium influx (and mobilization from intracellular stores) by adrenaline, a mechanism that is mediated by alpha 2-adrenoceptors. As this effect is more pronounced in younger patients, increased adenylate cyclase sensitivity may prevail in the early and alterations in calcium influx-dependent mechanisms in the later phase of essential hypertension. The transition into a hypertensive state with reduced-reflex cardiovascular counterregulation codetermines the antihypertensive effectiveness of calcium antagonists in these patients.
F R
FR
Bühler
P
P
Bolli
P
P
Erne
W
W
Kiowski
F B
FB
Müller
U L
UL
Hulthén
B H
BH
Ji
D001132:Arm; D001792:Blood Platelets / Q000378:metabolism; D001794:Blood Pressure; D002118:Calcium / Q000502:physiology*; D003593:Cytoplasm / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D009543:Nifedipine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D009568:Nitrendipine; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D012039:Regional Blood Flow / Q000187:drug effects; D014661:Vasoconstriction
D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D009568:Nitrendipine; D009543:Nifedipine; D002118:Calcium